Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP

Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP

Oncolytic viruses are currently tested as a novel platform for cancer therapy. These viruses preferentially replicate in and kill malignant cells. Due to their microbial origin, treatment with oncolytic viruses naturally results in anti-viral responses and general immune activation. Consequently, th...

Full description

Bibliographic Details
Main Authors: Saskia V. Vijver, Sarah Danklmaier, Lisa Pipperger, Raphael Gronauer, Gabriel Floriani, Hubert Hackl, Krishna Das, Guido Wollmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
oncolytic virus
epitope
prediction
VSV (vesicular stomatitis virus)
MHC-I
T cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1100730/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1100730/full

Similar Items